G-quadruplex stabilized lipid micelles for serum-resistant drug delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Lipid micelles used for drug delivery face instability in vivo due to interactions with serum proteins, leading to premature release of encapsulated components before reaching their target, despite being above the critical micelle concentration.
Innovation Solution
The synthesis of lipid micelles comprising lipid-oligonucleotide conjugate molecules, where a portion of the oligonucleotide is capable of forming parallel G-quadruplex structures, enhances stability and allows for targeted drug delivery by using antisense oligonucleotides to disrupt the micelle and release the drug at the target site.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lipid micelles are used for drug delivery, then they can solubilize hydrophobic drugs, but they become unstable in vivo due to interactions with serum proteins leading to premature drug release
Solution Approach 1:
The patent modifies the chemical structure of lipid head groups by incorporating G-quadruplex forming sequences (G4FS) that can undergo conformational changes in response to specific stimuli. This structural parameter change enables the micelles to maintain stability under physiological conditions while allowing controlled disruption upon encountering the trigger sequence, thereby resolving the contradiction between stability and responsiveness to serum proteins
Solution Approach 2:
The invention creates composite micelle structures combining conventional lipid components with oligonucleotide-based G-quadruplex forming sequences. This composite approach integrates the drug solubilization capability of lipid micelles with the stability and stimulus-responsiveness of nucleic acid structures, achieving both serum stability and controlled drug release
2Reliability
If micelles are stabilized through chemical crosslinking or covalent linkages, then stability improves, but the complexity of synthesis and manufacturing increases
Solution Approach 1:
The patent employs self-assembly mechanisms where lipid-oligonucleotide conjugates spontaneously form micelles with G-quadruplex structures through non-covalent interactions. This self-service approach eliminates the need for complex chemical crosslinking or covalent bonding steps, achieving stable micelle formation through natural molecular recognition and self-organization, thereby reducing synthesis complexity while maintaining stability
Solution Approach 2:
The invention replaces mechanical/chemical stabilization methods (crosslinking, covalent bonding) with molecular recognition-based stabilization through G-quadruplex formation. This substitution uses specific nucleic acid base pairing and stacking interactions instead of harsh chemical crosslinking agents, simplifying the synthesis process while achieving comparable or superior stability
3Reliability
If micelles remain stable in serum for extended periods, then drug delivery to target improves, but controlled release at the target site becomes difficult to achieve
Solution Approach 1:
The patent incorporates dynamic G-quadruplex forming sequences that can reversibly change conformation in response to specific stimuli such as antisense oligonucleotides or changes in ionic environment. This dynamic property allows the micelles to maintain stability during circulation while enabling controlled disassembly and drug release at the target site, resolving the contradiction between stability and adaptability
Solution Approach 2:
The invention uses complementary oligonucleotide sequences as intermediaries that can specifically bind to and disrupt the G-quadruplex structures. These intermediary sequences act as triggers that mediate the transition from stable micelle form to disrupted release form, enabling controlled drug delivery without compromising prior stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly increases the stability and efficacy of drug delivery by maintaining micelle integrity in serum conditions and enabling controlled release of the drug at the target, enhancing the delivery efficiency compared to conventional micelles.
Implementation Method 1
a first portion of the oligonucleotide of the lipid-oligonucleotide conjugate molecules is capable of forming parallel G-quadruplex with other oligonucleotides of the same sequence
Implementation Method 2
Lipid micelles generated by the self-assembly of monomers represent an important class of nanoparticle
Data Source
AI summary
Methods and compositions for serum-stabilizing micelles for drug delivery or imaging agent delivery are provided, as well as methods and compositions to enhance micelle-mediated drug delivery. This invention provides a process for synthesizing a lipid micelle comprising one or more lipid-oligonucleotide conjugate molecules, the process comprising contacting an amount of lipid molecules with an amount of lipid-oligonucleotide conjugate molecules sufficient to create a lipid micelle comprising lipid-oligonucleotide conjugate molecules.